Published in Cancer Weekly, July 6th, 2004
"Combination chemotherapy used to treat patients with aggressive non-Hodgkin lymphoma is associated with neutropenia and subsequent infection, hospital admission and treatment delays. Hematopoietic growth factors (HGF) can prevent neutropenia and improve quality of life. We undertook a meta-analysis of six randomized and one nonrandomized trials to quantify the effect in previously untreated patients, and a simple cost-effectiveness analysis," researchers in England report.
"The trials compared HGF plus chemotherapy with chemotherapy alone. In total, there were 779...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.